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Objectives: Treatment switching occurs when patients in a randomized clinical trial switch from the treatment initially assigned to them to another treatment, typically from the
control to experimental treatment. This study discusses the issues this raises and possible approaches to addressing them in trials of cancer drugs.
Methods: Stakeholders from around the world were invited to a 1.5-day Workshop in Adelaide, Australia. This study attempts to capture the key points from the discussion and the
perspectives of the various stakeholder groups, but is not a formal consensus statement.
Results: Treatment switching raises challenging ethical issues with arguments for and against allowing it. It is increasingly common in cancer drug trials and presents challenges for
the interpretation of results by regulators, clinicians, patients, and payers. Proposals are offered for good practice in the design, management, and analysis of trials and wider
development programs for cancer drugs in which treatment switching has occurred or is likely to. Recommendations are also offered for further action to improve understanding of
the importance and challenges of treatment switching and to promote agreement between key stakeholders on guidelines and other steps to address these challenges.
Conclusions: The handling of treatment switching in trials is of concern to all stakeholders. On the basis of the discussions at the Adelaide International Workshop, there would
appear to be common ground on approaches to addressing treatment switching in cancer trials and scope for the development of formal guidelines to inform the work of regulators,
payers, industry, trial designers and other stakeholders.
Keywords: Clinical trials, Cancer, Treatment switching, Decision making, Ethics
Treatment switching in a trial occurs when patients in one group
switch from the treatment specified for that group to the treat-
ment specified for another group in the trial (most commonly
from the control group treatment to the experimental group
treatment), or to another treatment that is not part of the origi-
nal trial protocol. Treatment switching as defined here is some-
times referred to as “crossover,” but we use the term “treatment
switching” in this study to avoid confusion with trials that have
a crossover design (whereby each patient is intended to receive
both treatments and act as their own “control”) (1).
Treatment switching may help to ensure that patients in
the trial are not denied access to new treatments when they
and/or their doctors believe that those treatmentsmay offer them
benefit. But it can lead to challenges in the interpretation of the
findings of the trial for the patients and doctors taking part in the
trial, for future patients and the doctors who will treat them, for
regulators, for payers (bywhichwemean those in health systems
or health insurance plans responsible for deciding whether, and
if so how much, the system or plan will pay or reimburse for a
drug), and hence for companies developing and marketing new
drugs (2).
Funding for the Adelaide Workshop was provided by Bellberry, Amgen, AstraZeneca, Janssen,
Merck Sharpe and Dohme, Pfizer and Roche.
Treatment switching appears to be increasingly common in
trials of some types of cancer drugs. A 2005 study reported
that crossover occurred in around 25 percent of all published
cancer trials (3), and a recent study reports that crossover was
present in trials of over half of the cancer drug appraisals con-
ducted by NICE in England (4). It is giving rise to a range of
concerns about how trials of cancer drugs can best be designed,
managed, analyzed, and interpreted. Some of these concerns
have been identified in scientific papers discussing statistical
and/or policy issues around treatment switching, but there has
been little formal discussion of the topic within and between
the stakeholder groups. The 2014 Adelaide International Work-
shop sought to address this by bringing together senior repre-
sentatives of key stakeholders from around the world to discuss
the issues, identify where there is agreement on appropriate
approaches to address treatment switching in the design and
analysis of cancer trials, and identify where further discussion
or work is needed.
METHODS
The Adelaide International Workshop was convened by Bell-
berry, a not for profit organization that exists to promote and
improve the welfare of research participants and the quality,
efficiency, and effectiveness of research. The Workshop was
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conducted over 1.5 days in October 2014. Forty-one people at-
tended from patient organizations, regulators, health technology
assessment (HTA)/payer bodies, universities (ethicists, statisti-
cians and health economists), and life sciences companies from
Australasia, Europe, and North America (the Supplementary
Table lists all participants and their affiliations). The program
included a range of presentations, with most of the time dedi-
cated to plenary and break-out group discussions. All attendees
received in advance a detailed agenda for the meeting, a back-
ground paper (5), details of several case studies for discussion,
and copies of guidance on treatment switching published or in
development by bodies around the world. The development of
these materials was overseen by a Scientific Committee (see
Supplementary Table for a list of members).
All participants agreed that those attending the Workshop
should be free to report anything that was said in the discus-
sions, but not which participants said it. They also agreed that
the background paper should be publicly available (see Supple-
mentary Material) but that the detailed case studies, the report
for participants of points made in the various sessions, and the
slides presented should be available only to participants. These
arrangements were designed to protect potentially sensitive in-
formation and to promote free and open discussion by ensuring
the confidentiality of individuals’ contributions.
This study represents the authors’ attempt to capture what
emerged from extended discussions between multiple stake-
holders at the Workshop. It has benefited greatly from com-
ments from attendees on drafts of an earlier study but it is not
intended to comprise a consensus statement from those present
at the Workshop or the organizations they are associated with,
or a statement of the policies of any of those organizations.
It is offered as a contribution to the debate, with the aim of
stimulating further discussions (and hopefully agreement and
action) within and, importantly, between the various stakeholder
groups, at national and international levels.
RESULTS
Context
It was clear from discussions at the Workshop that a number of
wider contextual factors need to be understood when consider-
ing treatment switching in cancer trials.
Drug Development Paradigms. There is increasing pressure to achieve
faster testing and approval of promising drugs so that patients
can get earlier access (6). This is leading to increased use of
“fast track” paradigms for regulatory approval (7) and is in-
fluencing the design of many clinical development programs.
This is often associated with a greater reliance on intermediate
end points (such as progression-free survival, PFS) in trials for
licensing (8–10). There are also concerns about the possible im-
pact on innovation of any further increases in the already high
cost of bringing drugs to market, and this is causing increased
scrutiny of the evidence required by regulators and by those
responsible for reimbursement. At the same time, there is an
increase in targeted therapies with associated challenges in re-
cruiting the numbers of patients required to allow clear answers
to be obtained from trials.
Cancer Care. Trial participation is increasingly seen as part of rou-
tine care for cancer patients, with many health systems seeking
to increase participation and with some using it as a measure
of the quality of care (11). While there are schemes in some
health systems to allowpatients special access (e.g., Therapeutic
Goods Administration, 2015) (12), patients may see enrolment
in a trial as a way to gain early access to new treatments. Patients
livingwith cancer, particularly those facing a terminal diagnosis
with no effective therapeutic options, naturally place high hopes
on new treatments. But, while significant improvements in sur-
vival have been achieved in a small number of cancers, there
are concerns that for many cancers new drugs offer relatively
modest improvements in PFS and/or overall survival (OS). Fur-
thermore, the extension in life is often associated with exposure
to significant drug toxicity and high financial cost (e.g., Fogo
et al.) (13). Patients and their doctors therefore need information
on health related quality of life (HRQoL) and outcomes such as
tolerability, symptoms, and functioning, as well as PFS and OS.
Given this context, treatment switching is usually found in trials
involving patients with incurable cancer rather than in studies
where long term cure is the goal.
Regulatory Evidence Requirements. Regulators are tasked with assessing
the balance of benefit and risk for a drug and granting market
access for those where the benefits outweigh the risks. While
they regard OS as a key outcome, in some clinical settings, they
are prepared to approve a drug on the basis of improvements in
PFS, symptoms or HRQoL if those improvements are clinically
significant and outweigh any potential harms or adverse effects,
and there are grounds to believe that the drug will improve OS
(or at least that there will be no detriment in OS) (6;8;9;14).
Payer Evidence Requirements. Payers are tasked with considering the
benefit that a drug offers (as assessed by its effects on patient
outcomes and the quality of care provided) in relation to its
cost, to determine either whether a drug is appropriate for their
healthcare system or plan at the price at which the manufacturer
offers it, or to determine the price the system will offer the
manufacturer given the extent of benefit demonstrated.
Most systems or plans have defined resources tomeet awide
and growing range of demands for care. In many systems, the
payer is required to consider value for money to promote equity
of access to benefit for patients across the system. Many payers
are therefore interested in the overall benefit a drug delivers in
relation to its cost. In most systems, overall benefit is judged in
relation to the length and quality of a patient’s life (reflecting
both the benefits and adverse effects of a treatment) following
treatment (15–18). This means that where a drug is able to
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demonstrate a benefit in PFS but cannot demonstrate benefit in
OS and HRQoL, the manufacturer may be expected to propose
or accept a lower price (often substantially lower) than would
be agreed for an OS benefit. If the manufacturer does not feel
able to accept this, the result may be that the drug is not covered
or reimbursed in the system, or the manufacturer decides not to
make the drug available at the price the system is prepared to
pay. In either case, some or all patients in the system will then
be denied access to the drug.
Randomized Controlled Trials and the Implications of Treatment Switching
The Workshop noted that randomized controlled trials (RCTs)
are generally accepted as the best way to establish differences
between treatment alternatives for the patient populations from
which the trial participants are selected. Observational studies
can play an important part in interpreting the relevance of trial
findings to wider populations and monitoring outcomes in the
real world following approval, but they are generally not con-
sidered to provide as reliable an indication of treatment effects
as RCTs. Thus, RCTs remain key to the assessment of new
treatments by regulators, payers, clinicians and patients.
Treatment switching introduces bias into a trial from the
point of switching onward. A range of methods is available for
analyzing and interpreting the results of trials where treatment
switching has occurred. These are discussed inmore detail in the
companion paper to this study (19). As noted there, key stake-
holders express differing degrees of confidence in such meth-
ods to adjust for switching. When the assumptions involved in
these methods are met and the rates of treatment switching are
not too high, published research has demonstrated that some
of the methods can provide reliable estimates of “true” treat-
ment effects (i.e., the treatment effect that would have been
demonstrated if no treatment switching had occurred). Often,
however, the assumptions are not fully met, and/or it is difficult
to ascertain whether or not they are met, and/or the proportion
of patients switching treatments is high. In practice, decision
makers are often reluctant to place confidence in estimates of
treatment effects derived from the analysis of trials with treat-
ment switching, particularly when the analytic methods are not
well explained or justified, or are based on assumptions that
have not been (or cannot be) justified.
The impact of treatment switching depends on when and
why it occurs, and on the outcomes of interest. If treatment
switching occurs at disease progression, this should generally
not affect the ability of a trial to establish differences in PFS
between the control and experimental groups (though the knowl-
edge that a patient can switch may introduce bias in not fully
blinded trials). Other subsequent end points, in particular OS,
adverse effects, potential harms, and other measures relating
to HRQoL post-progression will, however, be affected. If treat-
ment switching occurs because of a perceived loss of equipoise
resulting from an interim analysis or from information or events
outside the trial (e.g. regulatory approval being granted for use
in later lines of treatment; results becoming available from other
trials of the treatment or of similar agents), the trial’s ability to
establish differences in all outcomes, beneficial and harmful,
will be affected.
Given the impact of switching on the validity of trials and
their utility for decision makers, there was extensive discussion
at the Workshop of the implications of switching for the ethics
and the management of trials.
It was noted that, in general, the primary purpose of con-
ducting medical research is to generate knowledge that will be
of benefit to the future treatment of patients—whether those in
the research or others with the same condition. Reliable knowl-
edge generation is an important factor in ensuring that clinical
research is ethical (20). While this goal can never take prece-
dence over the rights and interests of individual research sub-
jects (21), it was believed that patients consenting to take part
in trials of any treatment should understand that the primary
purpose of medical research is to generate new knowledge.
Cancer trials raise some particular ethical issues. In con-
ditions with terminal diagnoses, patients may assume that the
benefits of an unproven new drug may outweigh any adverse
effects or risks and that it is worth trying and/or risking. As
noted previously, patients may enroll in a trial of a new cancer
drug in the hope of gaining early access to the drug, particularly
if there are no valid alternatives available. While there should
in theory be equipoise about the relative benefits of treatments
being offered to patients in a trial, many patients participating
in cancer trials appear to be doing so in the hope of personal
benefit during the trial.
Trials need to be conducted so as to provide reliable infor-
mation to inform the future treatment of all patients with the
condition (possibly including the trial participants themselves),
while ensuring that those participating in the trial are not dis-
advantaged and are given the best chance of optimal outcomes
at all stages. In trials in general, this balance is achieved by
defining in the trial protocol arrangements for interim analysis
to establish whether or not equipoise still exists and, if it does
not and one treatment has been shown to be superior, to allow
all patients to switch to that treatment. But patients in cancer
trials may also switch on disease progression and/or when infor-
mation from outside the trial leads patients and/or clinicians to
believe (on whatever grounds) that the experimental treatment
is superior. Switching in cancer trials is particularly likely when
there are no further active treatments available for patients after
progression, or when the drug being used in the experimental
arm of the trial has already been granted regulatory approval
for use in later lines of treatment (even if the trial in question is
investigating earlier lines).
As noted earlier, if the primary outcome of the trial is PFS,
then switching at progression will not affect the trial’s ability
to detect an effect on PFS. It will, however, affect its ability
to detect other subsequent benefits and harms that may be of
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relevance to the patients in the trial as well as future patients.
Furthermore, it may not always be in the interests of patients in
the trial to switch at disease progression or on demonstration of
a benefit of the experimental drug on PFS. Patients vary in their
responses to treatments, and a drug that improves PFS will not
necessarily improve postprogression survival (PPS) or quality
of life (22;23), so that a patient in the control groupwho is doing
well on the control treatment may sometimes be better advised
to stay on that treatment rather than switch.
The arguments for and against allowing treatment switching
in a trial therefore depend upon the nature and stage of the dis-
ease, the nature of the benefits and any harms that are expected
from the treatment, the nature of the primary and secondary
end points being studied, and the nature of the treatments cur-
rently available for patients in the trial and at later stages in their
disease. There is no single optimal approach.
At a practical level, treatment switching has become an es-
tablished part of trials in some areas of cancer. Patients choose
whether or not to enroll in trials and are free to withdraw from
a trial at any point, and in some situations (particularly where a
drug is already approved for other indications), clinicians may
be able to prescribe the treatment in the experimental arm of
a trial outside the trial if they believe it is in the patient’s best
interest. Recruiting and retaining patients in trials is becoming
increasingly problematic if treatment switching is not permitted.
It is therefore important that agreement is reached between pa-
tients, clinicians, regulators, payers, and manufacturers on how
switching will be addressed in the design and analysis of trials.
Statistical Methods
Attendees at theWorkshop discussed various statisticalmethods
for handling treatment switching in the analysis of a trial and, in
some cases, combining data from outside the trial in the analysis
of, and/or decision making based upon, the trial findings. These
issues are developed in detail in Latimer et al. (19). As noted
there, there is no single optimal approach to analyzing and
interpreting the data from trials where treatment switching has
occurred. The choice of methods will depend upon the nature
of the trial, the extent of treatment switching and the point(s) at
which it has occurred, the extent to which the assumptions of
different statistical approaches are met and can be shown to be
met within the setting of the trial, and the availability of data to
support the application of those approaches.
Proposals for Good Practice in Relation to Treatment Switching
Despite the complexity of the issues involved and the range
of perspectives represented at the Workshop, the discussions
pointed up a number of ways in which the handling of treatment
switching could be better addressed. We bring these together
here in some proposals for good practice which we hope will
be helpful—in themselves and as a stimulus to further debate
that may ultimately lead to more formal guidelines—to those
planning new trials and clinical development programs, and
to those seeking to manage and analyze existing trials where
treatment switching has occurred or is likely to occur. Table 1
provides a summary of recommendations.
Planning Clinical Trials and Clinical Development Programs
a.Companies designing clinical development programs for can-
cer drugs should discuss with patient advocates, clinicians, reg-
ulators, and payers the key outcomes that the program needs
to demonstrate to support informed decisions on market ap-
proval, reimbursement/coverage, and use of the drug. They
should consider carefully the importance to decision makers of
evidence on OS, adverse effects and other aspects of HRQoL,
and PFS, and ways in which this evidence can best be devel-
oped through trials and other studies to meet each stakeholder’s
requirements.
b. To maximize the chances to address treatment switch-
ing at the time of analysis, and hence the value of the trial,
trial protocols should define clearly and justify if, when and
on what basis treatment switching will be allowed within the
trial, in particular whether it will be at some predefined stage
of the progression of the patient’s disease (or when a patient no
longer benefits from treatment, for example, due to toxicity or
if maximum benefit has been achieved) or at loss of equipoise
following a predefined interim analysis of all the trial data. The
protocol should also state how requests from patients to switch
treatments in other circumstanceswill be handled. The approach
adopted should reflect the nature and stage of disease of the pa-
tients being recruited into the trial, the expected course of the
disease within and beyond the trial, the known effectiveness of
the control treatment within the trial, and the availability and ef-
fectiveness of further treatments beyond the trial. The approach
adopted should reflect discussions with patient advocates and
with payers as well as with clinicians and regulators.
c. To increase the likelihood of analysis of the trial data
being valid and convincing, when a trial protocol allows for
or envisages the possibility of treatment switching, it should
specify the methods by which it is anticipated the results will be
analyzed to take appropriate account of the likely effects of treat-
ment switching, and these methods should be discussed in ad-
vance with key decision makers such as regulators, HTA/payer
bodies and patient representatives. The methods should reflect
the nature and timing of the treatment switching to be allowed
and the expected extent of switching. The trial protocol should
define how data that are required from within the trial to apply
the chosen methods of analysis will be collected. The protocol
should also define how all patients will be followed up after they
stop their randomized treatment to collect information required
to analyze the trial outcomes. An analysis plan should describe
what analyses will be undertaken to provide information on the
plausibility of the key assumptions associated with the applied
adjustment methods. Where switching is to be allowed, and
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Table 1. Summary of recommendations
Planning clinical trials and clinical development programmes
• Discuss and agree key outcomes and study endpoints with stakeholders
• Define whether and in what circumstances treatment switching will be permitted, as part of the trial protocol
• Define how data collection, analysis, and sample sizes in the trial will allow conclusions to be drawn on key outcomes and end points if treatment switching occurs
• Identify the type and feasibility of additional studies that may be required if treatment switching is permitted in the pivotal trial
Managing clinical trials
• Research ethics committees should ensure that the trial end points and approach to treatment switching are appropriate, and that the proposed analyses of data from within and
beyond the trial will allow valid conclusions to be drawn
• The proposed approach to treatment switching in a trial should be explained to patients when consent is sought
• Trial sponsors and clinicians should monitor developments in related studies and ensure trial patients receive timely and balanced information through appropriate channels on
any emerging findings of relevance from within or outside the trial
Analyzing clinical trials
• When treatment switching occurs, a standard ITT analysis may be supplemented by analyses that attempt to adjust for switching
• The choice of adjustment method should reflect the nature of the trial, the nature and extent of the switching that has occurred, and the pivotal assumptions of the various
adjustment methods
• The proposed approach to analysis should be discussed with key decision makers, including options in addition to statistical adjustment methods where the impact of treatment
switching is likely to be important
Recommendations for further action
• Further discussion is needed between key stakeholders, including HTA and payer bodies, to reach agreement on general approaches and policies to address treatment switching
in cancer trials
• Work by multi-stakeholder groups is recommended to develop guidance on good practice for:
o Methods and mechanisms for ongoing engagement with stakeholders
o Approaches to treatment switching for different disease stages, trial end points, and treatment landscapes
o Matching statistical adjustment methods and trial designs
o Methods for integrating data from trials with data from observational and other studies outside the trial protocol
o Use of information from these sources and techniques in regulatory and coverage decisions
producing statistically significant OS results is the objective,
trial sponsors should consider basing sample size calculations
on anticipated applications of adjustment methods. See Latimer
et al. for a fuller discussion of these issues (19)
d. Clinical development programs should consider stud-
ies in addition to new trials that can be used to provide more
information on: (i) the likely effect of treatment on key trial
outcomes, for comparison or combination with data from the
trial to allow an estimate of the “true” treatment effects to be
made with more confidence; and/or (ii) outcomes not addressed
(or inadequately addressed) as a result of omission from the trial
protocol, of the powering of the trial, or confounding caused by
treatment switching; and/or (iii) the relevance of the trial results
for wider patient populations.
Such studies might include the post-trial follow-up of trial
patients, the analysis of patient data from other trials not im-
pacted by treatment switching, and observational studies of co-
horts of relevant patients. These external sources of information
may be useful in supplementing analyses of the trial data them-
selves to determine what the effect of the new treatment would
have been had treatment switching not occurred.
e.Research ethics committees and others responsible for the
review and quality assurance of trial protocols should satisfy
themselves that: (i) the definition of trial end points and the
approach to treatment switching and analysis of the trial results
are clear and appropriate; (ii) the approach reflects discussion
with patient advocates, protects the interests of patients in the
trial, and will deliver information to improve the treatment of
patients in the future; (iii) the arrangements and rationale for
treatment switching are made clear in the information patients
will be given about the trial when their consent is sought; and
(iv) proposals for the collection and analysis of data fromwithin
and beyond the trial will allow conclusions to be drawn from
the findings of the trial.
Managing Clinical Trials
a. The approach to treatment switching and the way in which
this protects the interests of patients in the trial and will deliver
information to improve the treatment of patients in the future
should be explained and discussed with patients when they are
invited to join a trial and asked to give their informed consent.
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b. The trial sponsor should maintain regular communica-
tion with all clinicians participating in a trial, and clinicians
should maintain regular communication with patients in their
local trial centers. When information arises from within or out-
side the trial that participating patients and/or clinicians may
see as relevant to their views on the effectiveness for them of
the treatments in the different arms of the trial, this should be
communicated to and discussed with trial participants. Where
possible, this should be accomplished ahead of disclosure to
the media or others, to ensure that trial participants receive bal-
anced information that can help them make informed decisions
about their best interests and their ongoing participation in the
trial, with or without switching treatment, or withdrawal from
the trial. In this regard, wherever possible and appropriate, in-
dustry and other trial sponsors should have discussions with
patient advocates and patient associations. Careful contingency
planning may be required, because information, accurate and
inaccurate, can spread quickly in some situations.
Analyzing Clinical Trials
a. In the presence of treatment switching that is deemed to
materially affect the results of a trial, a standard ITT analysis
may be supplemented with analyses that attempt to adjust for
switching and which may help to address the particular decision
problems faced by different stakeholders.
b. Where adjustment methods are used, trial characteristics
and the treatment switching mechanism should be considered
alongside the pivotal assumptions associated with each of the
statistical adjustment methods to identify which of the analyses
(ITT or any of the adjusted analyses) are likely to provide the
least amount of bias in each case. Concerns over the validity of
methodological assumptions should be addressed as far as pos-
sible using the types of analyses described in Latimer et al. (19).
Detailed justifications should be provided for chosen methods,
and consideration should be given to the direction of bias if
methodological assumptions are not satisfied. The sensitivity
of results should be tested through application of all methods
deemed to be potentially appropriate for each case (if a range
of methods can be shown to be potentially appropriate for a
particular case, and each provides similar estimates of the treat-
ment effect, decision makers may have more confidence in the
results).
c. Decision makers vary as to whether and when they are
prepared to consider the results of statistical adjustment meth-
ods. Therefore, trial designers and sponsors should wherever
possible discuss their proposed approach to analysis with key
decision makers to agree upon a preferred approach in the light
of the nature of the trial and the switching that has actually
occurred, building upon pre-trial discussions and the analysis
proposals included in the trial protocol (see above).
d. In circumstanceswhere the impact of treatment switching
is likely to be important, statistical adjustment methods are
not the only avenue that may be explored when attempting to
address treatment switching. Other options exist (see Latimer
et al. [19]). These should be discussed with key decision makers
as views on their validity and relevance vary.
DISCUSSION AND RECOMMENDATIONS FOR FURTHER ACTION
The Adelaide Workshop was a valuable first step toward identi-
fying the wide range of issues raised by treatment switching in
cancer trials, the views of different stakeholders on these, and
priorities for further work. There was good agreement on what
the challenges are and on the need to address them in the de-
sign and analysis of individual trials and through development
of more general guidance. There was also a good degree of
agreement on the specific strengths and weaknesses of different
approaches to analyzing trials where switching has occurred.
While all recognized that these methods have important lim-
itations, the level of understanding of these varied and views
differed on the extent to which such analyses could and should
be used to inform decisions. The Workshop did not reach spe-
cific conclusions about when treatment switching should be
recommended or discouraged, though there did appear to be
scope to reach agreement on situations where it would be more
and less appropriate.
On the basis of the Workshop discussions, we suggest the
following priorities for further action.
Further Discussion and Agreement on General Approaches and Policies to
Address Treatment Switching in Cancer Trials
There is a need for wider discussions to test the analysis of
the issues and the proposals for good practice set out in this
study through further multi-stakeholder discussions; different
stakeholders have different perceptions, expectations, decision
rules and requirements, and proposals need to take account of
all these considerations if they are to be adopted and be of value
in practice. It is particularly important to involve patients and
patient advocates in discussions because they are the people for
whom and with whom trials and associated studies are done. It
is also important to involve payers in the discussions because
they are the group for whom treatment switching at present
appears to present the greatest challenges. There is a need for
payers as a group to discuss the issues and possible solutions
to them, including the use of complex statistical methods to
analyze the results of trials with treatment switching. There is
also a need for payers to be brought into the wider discussions
so that their perspective and needs can be better understood by
the other stakeholders and so that payers can better understand
the patient perspective and the constraints that drug developers
and trial designers face.
Development of Guidance on “Good Practice” in the Design and Analysis of
Trials and Wider Clinical Development Programs for Cancer Drugs
We recommend work by multi-stakeholder groups to develop
more detailed guidance on good practice for: (a) Methods and
mechanism for achieving ongoing engagement with patients,
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clinicians, payers, and other stakeholders in discussions on treat-
ment switching. (b) Approaches to treatment switching for dif-
ferent disease stages, trial end points, and treatment landscapes.
(c) Matching the statistical approach to correct for treatment
switching to the trial design, and adapting the design of trials
andwider clinical development programs to support the analytic
approach. (d) Methods for integrating evidence from trials with
treatment switching, statistical adjustments to correct for that
switching, and data from observational and other studies from
outside the trial. (e) Approaches to using information from these
sources and techniques in regulatory and coverage decisions.
CONCLUSIONS
The management of treatment switching in trials is of concern
to all stakeholders. The perspectives and some of the specific
concerns of different stakeholders vary according to the nature
of the decisions they make and the systems they work within.
Nonetheless, on the basis of the discussions at the Adelaide In-
ternational Workshop, there appears to be a considerable com-
mon ground on approaches to addressing treatment switching
in cancer trials.
We hope that the proposals for good practice offered in
this study will be helpful to those designing, managing and
analyzing trials and wider clinical development programs for
cancer drugs. We also hope that they will provide a platform
for the development of more formal guidance to inform the
work of regulators, payers, industry, trial designers, and other
stakeholders.
The Adelaide meeting focused on treatment switching in
trials of cancer drugs. Some of the issues considered are specific
to cancer and cancer trials, but otherswould appear to be relevant
to trials of treatments for other diseases. It is hoped that the
discussion in this studywill also be of value to those considering
the design and analysis of trials in other areas where treatment
switching may be an issue.
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